Related Experiment Video
Updated: Jan 9, 2026
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape
Mingchao Xie1, Miljenka Vuko2, Shashank Saran3
1Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA, USA.
Background:
Greater understanding of differential therapeutic sensitivity, specifically to immunotherapy, in small-cell lung cancer (SCLC) is required.
Methods:
We explored SCLC heterogeneity through integrated molecular characterization of tumor tissue samples from 159 treatment-naive patients, utilizing genetic, epigenetic, transcriptional, and proteomic profiling, immunohistochemistry staining for multiple biologically relevant markers including transcriptional subtype-defining proteins, and spatial immune profiling using multiplex immunofluorescence.
Results:
Multi-omics analysis confirmed high heterogeneity across/within neuroendocrine and non-neuroendocrine subtypes. Methylomics analysis identified four methylome clusters that may enhance subtype prediction, prognosis, and longitudinal monitoring of subtype evolution. Immunohistochemistry analysis showed high MHC-I expression in non-neuroendocrine subtypes, which have greatest potential benefit from adding immunotherapy to chemotherapy; high DLL3 expression associated with neuroendocrine subtypes and an immune-cold tumor microenvironment. Multiplex immunofluorescence demonstrated associations of MHC-I with spatial arrangement and phenotypic features of immune cells in the tumor microenvironment of high-MHC-I-expressing SCLC, providing mechanistic rationale for MHC-I as a potential biomarker of immunotherapy response.
Conclusions:
This multimodal profiling analysis provides further insights into the biologic complexity of SCLC and highlights potential therapeutic vulnerabilities of distinct disease subtypes.
Insights
Understanding small-cell lung cancer (SCLC) heterogeneity is key for effective immunotherapy. This study reveals distinct subtypes with varying responses, identifying potential biomarkers like MHC-I for improved treatment strategies.
Area of Science:
- Oncology
- Translational Research
- Genomics
Background:
- Small-cell lung cancer (SCLC) exhibits significant therapeutic resistance, necessitating a deeper understanding of its heterogeneity.
- Differential sensitivity to therapies, particularly immunotherapies, remains poorly understood in SCLC subtypes.
Purpose of the Study:
- To comprehensively characterize SCLC heterogeneity using integrated multi-omics profiling.
- To identify molecular features associated with distinct SCLC subtypes and their potential therapeutic vulnerabilities.
Main Methods:
- Integrated molecular characterization of 159 treatment-naive SCLC patient tumor samples.
- Utilized genetic, epigenetic, transcriptional, proteomic, and spatial immune profiling.
- Included immunohistochemistry for subtype-defining proteins and multiplex immunofluorescence.
Main Results:
- Confirmed substantial heterogeneity within and across neuroendocrine and non-neuroendocrine SCLC subtypes.
- Identified four methylome clusters potentially aiding subtype prediction and monitoring.
- Observed high MHC-I expression in non-neuroendocrine subtypes (potential immunotherapy benefit) and high DLL3 in neuroendocrine subtypes (immune-cold phenotype).
Conclusions:
- Multimodal profiling deepens insights into SCLC's biological complexity.
- Identified distinct SCLC subtypes with specific therapeutic vulnerabilities.
- Highlights MHC-I as a potential biomarker for immunotherapy response in SCLC.
